RT Journal Article
SR Electronic
T1 A cluster randomised trial of the impact of a policy of daily testing for contacts of COVID-19 cases on attendance and COVID-19 transmission in English secondary schools and colleges
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.23.21260992
DO 10.1101/2021.07.23.21260992
A1 Bernadette C Young
A1 David W Eyre
A1 Saroj Kendrick
A1 Chris White
A1 Sylvester Smith
A1 George Beveridge
A1 Toby Nonnemacher
A1 Fegor Ichofu
A1 Joseph Hillier
A1 Ian Diamond
A1 Emma Rourke
A1 Fiona Dawe
A1 Ieuan Day
A1 Lisa Davies
A1 Paul Staite
A1 Andrea Lacey
A1 James McCrae
A1 Ffion Jones
A1 Joseph Kelly
A1 Urszula Bankiewicz
A1 Sarah Tunkel
A1 Richard Ovens
A1 David Chapman
A1 Peter Marks
A1 Nick Hicks
A1 Tom Fowler
A1 Susan Hopkins
A1 Lucy Yardley
A1 Tim EA Peto
YR 2021
UL http://medrxiv.org/content/early/2021/07/25/2021.07.23.21260992.abstract
AB Background School-based COVID-19 contacts in England are asked to self-isolate at home. However, this has led to large numbers of missed school days. Therefore, we trialled daily testing of contacts as an alternative, to investigate if it would affect transmission in schools.Methods We performed an open-label cluster randomised controlled trial in students and staff from secondary schools and further education colleges in England (ISRCTN18100261). Schools were randomised to self-isolation of COVID-19 contacts for 10 days (control) or to voluntary daily lateral flow device (LFD) testing for school contacts with LFD-negative contacts remaining at school (intervention). Household contacts were excluded from participation.Co-primary outcomes in all students and staff were symptomatic COVID-19, adjusted for community case rates, to estimate within-school transmission (non-inferiority margin: <50% relative increase), and COVID-19-related school absence. Analyses were performed on an intention to treat (ITT) basis using quasi-Poisson regression, also estimating complier average causal effects (CACE). Secondary outcomes included participation rates, PCR results in contacts and performance characteristics of LFDs vs. PCR.Findings Of 99 control and 102 intervention schools, 76 and 86 actively participated (19-April-2021 to 27-June-2021); additional national data allowed most non-participating schools to be included in the co-primary outcomes. 2432/5763(42.4%) intervention arm contacts participated. There were 657 symptomatic PCR-confirmed infections during 7,782,537 days-at-risk (59.1/100k/week) and 740 during 8,379,749 days-at-risk (61.8/100k/week) in the control and intervention arms respectively (ITT adjusted incidence rate ratio, aIRR=0.96 [95%CI 0.75-1.22;p=0.72]) (CACE-aIRR=0.86 [0.55-1.34]). There were 55,718 COVID-related absences during 3,092,515 person-school-days (1.8%) and 48,609 during 3,305,403 person-school-days(1.5%) in the control and intervention arms (ITT-aIRR=0.80 [95%CI 0.53-1.21;p=0.29]) (CACE-aIRR 0.61 [0.30-1.23]). 14/886(1.6%) control contacts providing an asymptomatic PCR sample tested positive compared to 44/2981(1.5%) intervention contacts (adjusted odds ratio, aOR=0.73 [95%CI 0.33-1.61;p=0.44]). Rates of symptomatic infection in contacts were 44/4665(0.9%) and 79/5955(1.3%), respectively (aOR=1.21 [0.82-1.79;p=0.34]).Interpretation Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission. COVID-19 rates in school-based contacts in both intervention and control groups were <2%. Daily contact testing is a safe alternative to home isolation following school-based exposures.Competing Interest StatementDWE reports lecture fees from Gilead outside the submitted work. RO and DC are consultants employed by DHSC as part of Deloitte's broader project work supporting the delivery of NHS Test and Trace. TF reports honoraria from Qatar National Research Fund (QNRF) outside the submitted work, no other author has a conflict of interest to declare.Clinical TrialISRCTN18100261Funding StatementThis study was funded by the UK Government Department of Health and Social Care and supported by the UK Government Department for Education and Office for National Statistics. The work was also supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE) (NIHR200915) and the NIHR Biomedical Research Centre, Oxford. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care, the Department for Education, the Office for National Statistics or Public Health England. BCY is an NIHR clinical lecturer. BCY, TEAP and LY received grants from DHSC to fund this work. DWE is a Robertson Foundation Fellow.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and ethical approved granted by Public Health England's Research Ethics and Governance Group (ref R&D 434). The study was done in accordance with the Declaration of Helsinki and national legislation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the trial will be available within the Office for National Statistics Secure Research Service. Applications for access can be made by Accredited Researchers. For more details please see - https://cy.ons.gov.uk/aboutus/whatwedo/statistics/requestingstatistics/approvedresearcherscheme.